{"a":[{"_":"Analysts ‘extremely bullish’ as Telix beams into Novartis’ territory with $1.6B ITM acquisition","$":{"href":"/biotech/analysts-extremely-bullish-telix-beams-novartis-territory-165b-itm-acquisition","hreflang":"en"}}]}

Summary

Telix Pharmaceuticals has agreed to acquire ITM Isotope Technologies Munich for $1.65 billion upfront, gaining access to a radiopharmaceutical R&D pipeline that competes with Novartis' Lutathera and a radiopharmaceutical supply network.